Active Projects

IBD HAS NO AGE is an EFCCA campaign started in 2022 in order to raise awareness of how Inflammatory Bowel Disease (IBD) is impacting on the life of people aged 60 years and over. This year, for World IBD Day 2023 (19 May), we will launch a survey on people with IBD aged 60 years and over to investigate more on this topic with questions related to both quality of care and quality of...
The METHYLOMIC project will build on multiple previous cohort studies that confirmed epigenetic biomarkers (specifically DNA methylation) as the most stringent predictor of response to biological therapy, zooming in on CD. DNA methylation profiles in peripheral blood as biomarkers of response/deep remission for three approved biologicals in CD have been specifically discovered and validated....
The GlycanTrigger project proposes a thorough and innovative approach to understand better the health-to-chronic inflammation transition occurring in patients with CD that will be translated into improved disease prediction and prevention. The project aims to do so by addressing how changes in glycosylation of the gut mucosa act as a primary event that dysregulates not only local mechanisms (...
The GENEGUT project will transform the treatment of ileal CD by developing a first-in-class oral RNA-based therapy, tackling inflammation locally in the intestinal tissue, while avoiding systemic side effects. Despite advances in new immune modulators and biological treatment, up to 30% of patients become non-responders. Besides, intestinal fibrosis is a significant challenge in Crohn’s...
EFCCA  is involved in an exciting EU Research Project under the Innovative Medicines Initiative (IMI 2) (Horizon 2020). The ImmUinverse project main goal is the improved diagnostic and therapeutic options for patients living with ulcerative colitis and atopic dermatitis. New insights into disease severity and progression will enable personalised therapy for each individual...
EFCCA is involved in this exciting project that will identify digital endpoints that provide reliable, objective and sensitive evaluation of activities of daily living and Health-related quality of life (HRQoL) in ImmuneMediated Inflammatory Diseases such as IBD as well as other such as Rheumatoid Arthritis and Lupus and which will ultimately have a positive impact on the quality of life of these...
There is very little scientific evidence on patient preference targeted at the IBD patient community. This is why EFCCA decided to embark on this project which started in 2020 with an in-depth literature review and a cooperation agreement with KU Leuven university (Belgium). KU Leuven had already run a country level survey on IBD patient preferences which,  together with other...
The European Crohn’s and Colitis Organisation [ECCO] produces and regularly updates several guidelines to provide evidence-based guidance on critical aspects of IBD care to all health care professionals who manage patients with IBD.  Since the initiation of the first project in 2006, the ECCO Guidelines have become standard references for IBD management in Europe and around the world. The...
Fatigue is an important underecognized clinical problem in patients with IBD and one of the most frequently reported concerns of patients. It affects nearly 50 % of patients in clinical remission and 80% of those with active disease, resulting in a decrease in quality of life and impaired work productivity and functioning. Fatigue is a debilitating, multidimensional and multifactorial...
One of our flagship activities in terms of patient empowerment is the EFCCA Academy. The Academy was launched in 2018 to provide specialized training for people with IBD enabling them to raise awareness on specific topics and to become advocates for their IBD patient community. Academy qualified patients will become trainers of trainers within their own local community. Training usually takes...